Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Market Cap
$2.31B
P/E Ratio
-4
1Y Stock Return
-34.44%
1Y Revenue Growth
-92.33%
Dividend Yield
0.00%
Price to Book
7.0
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NTLA | 50.82% | $1.44B | -50.35% | 0.00% |
PGEN | 49.64% | $228.91M | -28.00% | 0.00% |
CRNX | 47.82% | $5.12B | +84.27% | 0.00% |
BEAM | 45.97% | $2.09B | -9.52% | 0.00% |
EDIT | 44.99% | $204.72M | -75.49% | 0.00% |
ALEC | 44.51% | $377.04M | -19.46% | 0.00% |
CRSP | 44.16% | $4.01B | -30.49% | 0.00% |
ENTA | 43.13% | $199.60M | -5.52% | 0.00% |
KFRC | 41.69% | $1.10B | -8.71% | 0.66% |
PLRX | 41.49% | $778.32M | -9.55% | 0.00% |
DEA | 41.39% | $1.27B | +5.51% | 8.82% |
FATE | 40.34% | $248.29M | -11.02% | 0.00% |
RARE | 39.53% | $4.17B | +16.19% | 0.00% |
MARA | 39.31% | $6.39B | +92.63% | 0.00% |
VSH | 39.25% | $2.07B | -31.61% | 2.64% |
GBIO | 39.14% | $92.84M | +20.87% | 0.00% |
PRTA | 38.96% | $756.01M | -56.52% | 0.00% |
SKLZ | 38.93% | $93.29M | -16.05% | 0.00% |
SANA | 38.91% | $526.91M | -41.15% | 0.00% |
AKRO | 38.79% | $2.17B | +93.09% | 0.00% |
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
PASADENA, Calif., November 18, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to
Yahoo
PASADENA, Calif., November 18, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24) and PALISADE data was simultaneously published in the AHA journal, Circulation.
Finnhub
TIDES Europe 2024 Novel TRiM Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration ...
Yahoo
PASADENA, Calif., November 05, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024.
Yahoo
PASADENA, Calif., November 04, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Finnhub
PASADENA - Arrowhead Pharmaceuticals, Inc. today, on FCS Awareness Day, announced the launch of a new disease awareness campaign, 'We'll Get There Soon,' to bring hope to the rare disease community...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACI | 0.03% | $11.16B | -9.32% | 2.50% |
LNG | -0.04% | $49.37B | +24.99% | 0.82% |
UUU | -0.05% | $4.97M | -41.89% | 0.00% |
SRRK | 0.06% | $2.61B | +134.91% | 0.00% |
ASR | -0.07% | $7.56B | +26.22% | 0.00% |
SOC | -0.10% | $1.93B | +74.70% | 0.00% |
CMTL | -0.11% | $84.44M | -76.16% | 0.00% |
SIGI | -0.14% | $5.90B | -4.96% | 1.47% |
LTM | 0.21% | $8.51B | -100.00% | <0.01% |
PRT | 0.26% | $48.72M | -16.56% | 10.33% |
TTE | 0.29% | $138.45B | -11.95% | 5.50% |
CMG | -0.30% | $80.02B | +33.62% | 0.00% |
SOLV | -0.36% | $11.58B | -16.19% | 0.00% |
CLX | 0.36% | $20.81B | +20.66% | 2.88% |
CPB | 0.36% | $12.96B | +7.08% | 3.40% |
MNST | 0.44% | $52.25B | -1.95% | 0.00% |
AON | -0.48% | $82.00B | +16.33% | 0.70% |
GL | 0.60% | $9.18B | -8.60% | 0.86% |
CL | -0.61% | $76.48B | +22.25% | 2.12% |
QNST | 0.61% | $1.19B | +93.14% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
REX | -17.68% | $772.08M | +19.14% | 0.00% |
PGR | -14.86% | $149.10B | +57.29% | 0.45% |
XGN | -14.61% | $62.26M | +127.74% | 0.00% |
HUSA | -12.73% | $16.69M | -11.56% | 0.00% |
MCK | -11.25% | $78.15B | +35.51% | 0.42% |
CHD | -11.22% | $27.18B | +19.50% | 1.03% |
PHI | -10.73% | $4.83B | -1.80% | 7.58% |
CME | -10.58% | $82.76B | +9.21% | 1.98% |
COR | -10.47% | $47.48B | +21.20% | 0.86% |
STG | -10.31% | $35.67M | +7.92% | 0.00% |
CYD | -9.18% | $364.46M | -2.94% | 4.26% |
CBOE | -9.12% | $21.46B | +15.84% | 1.11% |
MOH | -8.08% | $16.16B | -21.56% | 0.00% |
KR | -7.40% | $42.03B | +35.08% | 2.11% |
PEP | -7.31% | $215.02B | -6.60% | 3.35% |
VHC | -7.06% | $19.06M | -38.36% | 0.00% |
ALL | -6.21% | $52.06B | +45.67% | 1.85% |
WRB | -6.18% | $22.94B | +29.98% | 0.69% |
CB | -5.89% | $114.43B | +26.00% | 1.24% |
ZCMD | -5.88% | $2.80M | -88.67% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SOYB | 0.21% | $27.32M | 0.22% |
SEIX | -0.30% | $268.81M | 0.62% |
TBLL | -0.41% | $1.92B | 0.08% |
FMF | -0.51% | $244.61M | 0.95% |
COMT | 0.55% | $829.06M | 0.48% |
XBIL | 0.72% | $637.70M | 0.15% |
DBE | 0.91% | $50.13M | 0.77% |
DBO | 0.95% | $217.57M | 0.77% |
GSG | 1.32% | $914.42M | 0.75% |
HIGH | 1.41% | $302.78M | 0.51% |
GBIL | 1.60% | $5.60B | 0.12% |
DUSB | 1.72% | $797.63M | 0.15% |
FTGC | 1.91% | $2.17B | 1.02% |
TAIL | -1.97% | $67.98M | 0.59% |
USCI | -2.01% | $185.47M | 1.07% |
FLTR | 2.06% | $1.79B | 0.14% |
BOXX | 2.74% | $4.43B | 0.1949% |
BILZ | -2.76% | $563.02M | 0.14% |
XHLF | 2.91% | $874.27M | 0.03% |
DBMF | -3.23% | $1.02B | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 61.17% | $70.59M | 0.5% |
XBI | 57.38% | $6.58B | 0.35% |
IBB | 55.18% | $6.66B | 0.45% |
FBT | 53.36% | $1.11B | 0.56% |
XPH | 52.00% | $157.87M | 0.35% |
BBH | 51.61% | $397.87M | 0.35% |
PTH | 50.72% | $143.31M | 0.6% |
ARKG | 50.16% | $1.13B | 0.75% |
PBE | 48.92% | $258.53M | 0.58% |
IWO | 46.92% | $12.56B | 0.24% |
VTWO | 46.28% | $12.38B | 0.1% |
KOMP | 46.19% | $2.09B | 0.2% |
PINK | 46.16% | $161.15M | 0.5% |
IWM | 46.08% | $75.73B | 0.19% |
ISCG | 46.00% | $640.00M | 0.06% |
ESML | 45.86% | $1.90B | 0.17% |
IWC | 45.59% | $933.99M | 0.6% |
RSPA | 45.43% | $273.87M | 0% |
SMMD | 45.33% | $1.24B | 0.15% |
NUSC | 45.29% | $1.27B | 0.31% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -38.75% | $388.04M | 1.43% |
USDU | -24.63% | $201.97M | 0.5% |
UUP | -24.40% | $309.25M | 0.77% |
VIXY | -20.74% | $195.31M | 0.85% |
CTA | -16.23% | $350.27M | 0.78% |
DBA | -14.68% | $755.88M | 0.93% |
CORN | -10.13% | $61.12M | 0.2% |
WEAT | -9.80% | $120.27M | 0.28% |
EQLS | -8.36% | $76.08M | 1% |
KMLM | -7.65% | $353.87M | 0.9% |
TBIL | -5.18% | $4.38B | 0.15% |
KCCA | -4.77% | $220.51M | 0.87% |
MINT | -4.40% | $11.62B | 0.35% |
AGZD | -4.14% | $142.76M | 0.23% |
HDRO | -3.81% | $164.26M | 0.3% |
BSCO | -3.35% | $2.35B | 0.1% |
DBMF | -3.23% | $1.02B | 0.85% |
BILZ | -2.76% | $563.02M | 0.14% |
USCI | -2.01% | $185.47M | 1.07% |
TAIL | -1.97% | $67.98M | 0.59% |
Current Value
$18.561 Year Return
Current Value
$18.561 Year Return